Alkermes, a biopharmaceutical company, is set to showcase its leadership in psychiatric research at the American Society of Clinical Psychopharmacology Annual Meeting. The company will present 11 posters highlighting its commitment to advancing innovative treatments for people living with chronic psychiatric and neurological disorders. These disorders include major depressive disorder, schizophrenia, and substance use disorders.
According to the National Institute of Mental Health, mental health conditions affect one in four people in the UK, with many struggling to access effective treatments. Alkermes' research aims to address this issue by developing novel therapies that target the underlying biology of these disorders. The company's focus on orexin biology, a key area of research, has shown promise in improving treatment outcomes for patients.
The American Society of Clinical Psychopharmacology Annual Meeting is a premier event for psychiatric research and development. Alkermes' presentations will be led by experts in the field, including Dr. Craig Hopkinson, Senior Vice President of Research and Development at Alkermes. Dr. Hopkinson stated, 'We are committed to advancing psychiatric research and development to address the significant unmet needs of patients living with chronic psychiatric and neurological disorders.'
Alkermes' research has been peer-reviewed and published in leading scientific journals. The company's dedication to advancing psychiatric research and development has been acknowledged by the scientific community. The UK's National Institute for Health and Care Excellence (NICE) has already approved several Alkermes' treatments for use in the UK healthcare system.
In the UK, Alkermes' research has the potential to improve treatment outcomes for thousands of patients living with mental health conditions. The company's commitment to advancing psychiatric research and development is a welcome development in the UK's efforts to address mental health challenges.
The American Society of Clinical Psychopharmacology Annual Meeting takes place from [date] to [date]. The meeting will feature presentations from leading experts in the field of psychiatric research and development. Alkermes' presentations will be available on the company's website following the meeting.